KCNH5
ENSG00000140015
Target class
Ion channel
Chromosome
14
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- KCNH5
- Gene name
- Potassium voltage-gated channel subfamily H member 5
- Gene symbol
- KCNH5
- Protein name
- Voltage-gated delayed rectifier potassium channel KCNH5 (Ether-a-go-go potassium channel 2) (hEAG2) (Potassium voltage-gated channel subfamily H member 5) (Voltage-gated potassium channel subunit Kv10.2)
- Kv10.2
- H-EAG2
- eag2
- hEAG2
- Gene biotype
- Protein coding
- Gene family
- Potassium voltage-gated channels|PAS domain containing
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 3
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 3.29
- Tissue specificity (Gini)
- 0.882
- Tissue specificity (tau)
- 0.962
- KEGG gene identifiers
- hsa:27133
- Reactome pathways
- R-HSA-1296072
- End position
- 63102037
- Start position
- 62699464
- Chromosome
- 14
- Strand
- Reverse
- Membrane
- Multi-pass membrane protein.
- Centrosome
- Cytosol
- Nucleoplasm
- Tissue specificity (tau)
- 0.962436
- Expression inequality (Gini)
- 0.881625
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 3.29
- Brain - Cortex
- 2.28
- Brain - Hypothalamus
- 1.15
- Brain - Anterior cingulate cortex (BA24)
- 0.91
- Pituitary
- 0.39
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)3.29
- Brain - Cortex2.28
- Brain - Hypothalamus1.15
- Brain - Anterior cingulate cortex (BA24)0.91
- Pituitary0.39
- Brain - Amygdala0.38
- Testis0.31
- Brain - Hippocampus0.17
- Brain - Substantia nigra0.13
- Adipose - Visceral (Omentum)0.12
- Brain - Nucleus accumbens (basal ganglia)0.12
- Brain - Spinal cord (cervical c-1)0.1
- Brain - Putamen (basal ganglia)0.08
- Brain - Caudate (basal ganglia)0.08
- Colon - Sigmoid0.07
- Prostate0.03
- Bladder0.03
- Vagina0.03
- Esophagus - Gastroesophageal Junction0.03
- Esophagus - Muscularis0.02
- Breast - Mammary Tissue0.02
- Colon - Transverse0.01
- Skin - Not Sun Exposed (Suprapubic)0.01
- Lung0.01
- Brain - Cerebellum0.01
And 29 more, listed on the interactive page.
- GO:0006813
- GO:0010389
- GO:0005886
- GO:0008076
- GO:0009986
- GO:0005249
- GO:0005251
Related records
Trials (140)
- 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
- 4-aminopyridine for Skin Wound Healing
- 4-Aminopyridine in Episodic Ataxia Type 2
- 4-Aminopyridine to Treat Skin Burns
- 4-aminopyridine Treatment for Nerve Injury
- 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy
- 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
- 4-AP Peripheral Nerve Crossover Trial
- 4AP for Carpal Tunnel Syndrome (CTS)
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
- A Phase 1 Study Comparing AVP-786 With AVP-923
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
- A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
- A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
- A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis
Drugs (9)
- Amifampridine Voltage-gated potassium channel blocker
- Amifampridine phosphate Voltage-gated potassium channel blocker
- Dalfampridine Voltage-gated potassium channel blocker
- Guanidine Voltage-gated potassium channel blocker
- Guanidine hydrochloride Voltage-gated potassium channel blocker
- Nerispirdine Voltage-gated potassium channel blocker
- Quinidine
- Tedisamil Voltage-gated potassium channel blocker
- Tedisamil sesquifumarate Voltage-gated potassium channel blocker